In vivo tumor delivery of a recombinant single-chain Fv::Tumor necrosis factor: A fusion protein

Bioconjugate Chemistry

Volumn 13, Issue 1, 2002, Pages 7-15

  Cooke, Stephen P ^a   Pedley, R Barbara ^a   Boden, R ^a   Begent, Richard H J ^a   Chester, Kerry A ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AFFINITY CHROMATOGRAPHY; ANTIBODIES; ANTIGENS; CELL CULTURE; CHAINS; DISEASES; MACROPHAGES; MAMMALS; ONCOLOGY; RECOMBINANT PROTEINS; TUMORS;

ANTITUMOR ANTIBODIES; ANTITUMOUR ACTIVITY; CANCER THERAPY; FUSION PROTEINS; IN-VIVO; NORMAL TISSUE; SINGLE-CHAIN FV; THERAPEUTIC DOSE; TUMOR GROWTH; TUMOR NECROSIS FACTORS;

GLYCOPROTEINS;

BACTERIA (MICROORGANISMS); MUS MUSCULUS;

ANTIBODY CONJUGATE; ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; HYBRID PROTEIN; IMMUNOGLOBULIN FRAGMENT; IMMUNOGLOBULIN FV; MFE 23 PROTEIN, HUMAN; MFE-23 PROTEIN, HUMAN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANIMAL; ARTICLE; BIOSYNTHESIS; CELL CULTURE; CHEMISTRY; DRUG DELIVERY SYSTEM; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; NEOPLASM; NUDE MOUSE; PROTEIN FOLDING; TISSUE DISTRIBUTION;

ANIMALS; ANTINEOPLASTIC AGENTS; CARCINOEMBRYONIC ANTIGEN; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNOCONJUGATES; IMMUNOGLOBULIN FRAGMENTS; MICE; MICE, NUDE; NEOPLASMS; PROTEIN FOLDING; RECEPTORS, TUMOR NECROSIS FACTOR; RECOMBINANT FUSION PROTEINS; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036369434     PISSN: 10431802     EISSN: None     Source Type: Journal    
DOI: 10.1021/bc000178a     Document Type: Article

References (34)

1. Phase 1 trial of human γ-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer
2. Studies of the antitumor efficacy of systemically administered recombinant tumor necrosis factor against several murine tumors in vivo
3. Purification and characterization of a Pichia pastoris expressed Mfe-23::CpG2 glycosylated fusion protein
4. High-resolution crystal structure of a human tumor necrosis factor-a mutant with low systemic toxicity
5. Suppression of Bcl-2 messenger RNA production may mediate apoptosis after ionising radiation, tumor necrosis factor α and ceramide
6. Phage libraries for generation of clinically useful antibodies
7. Clinical evidence of efficient tumor targeting based on single-chain Fv antibody selected from a combinatorial library
8. Tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity
9. Antibody characteristics can influence the effectiveness of Radioimmunotherapy by selectively targeting radiosensitive areas of tumor
10. Protein and cell membrane iodinations with a sparingly soluble chloroamide, 1,3,4,6-tetrachloro-3α,6α-diphenylglycoluril
11. Tumor pretargeting with avidin improves the therapeutic index of biotinylated tumor necrosis factor α in mouse models
12. Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins
13. Construction and expression of antibody-tumor necrosis factor fusion proteins
14. A novel protein required for apoptosis-mutational analysis of human Fas antigen
15. Tumor necrosis factor can induce both apoptotic and necrotic forms of cell lysis
16. High-dose recombinant tumor necrosis factor (rTNFα) administered by isolation perfusion for advanced tumors of the limbs: A model for biochemotherapy of cancer
17. Tumor necrosis factor alpha in isolated perfusion systems in the treatment of cancer: The Rotterdam pre-clinical program
18. Tumor necrosis factor alpha (TNFα) gene therapy targeted by ionising radiation selectively damages tumor vasculature
19. Regional biologic therapy: Hepatic arterial infusion of recombinant human tumor necrosis factor in patients with liver metastases
20. Radioimmunoguided surgery in colorectal cancer using a genetically engineered anti-CEA single chain Fv antibody
21. Phase 1 study of recombinant human tumor necrosis factor-α in advanced malignant disease
22. Tumor cell targeting with antibody-avidin complexes and biotinylated tumor necrosis factor alpha
23. 131I anti-CEA antibody in a colonic xenograft model
24. Ablation of colorectal xenografts with combined radioimmunotherapy and tumor blood flow modifying agents
25. In vitro and in vivo evaluation of human tumor necrosis factor alpha (hTNF alpha) chemically conjugated to monoclonal antibody
26. Cytokine targeting in tumors using a bispecific antibody directed against carcinoembryonic antigen and tumor necrosis factor alpha
27. Combination immunotherapy for cancer: Synergistic antitumor interactions of interleukin-2,α-interferon, and tumor infiltrating lymphocytes
28. Effect of tumor necrosis factor on the uptake of specific and control monoclonal antibodies in a human tumor xenograft model
29. An apoptosis-inducing gene therapy for pancreatic cancer with a combination of 55-kDa tumor necrosis factor (TNF) receptor gene transfection and mutein TNF administration
30. Cytotoxic and antitumor activity of recombinant tumor necrosis factor-B1(Fv) fusion protein on LeY antigen-expressing human cancer cells
31. Targeting of tumor necrosis factor to tumor by use of dextran and metal coordination
32. Toxic effect of tumor necrosis factor on tumor vasculature in mice
33. Recombinant human tumor necrosis factor causes regression in patients with advanced malignancies
34. A genetically engineered single-chain Fv/TNF molecule possesses the anti-tumor immunoreactivity of Fv as well as the cytotoxic activity of tumor necrosis factor